{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T04:42:02Z","timestamp":1784522522684,"version":"3.55.0"},"reference-count":60,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Am Coll Clin Pharm"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Opioid use disorder (OUD) is a chronic relapsing condition characterized by problematic opioid use causing significant impairment in daily life. Medication for opioid use disorder using buprenorphine, methadone, and naltrexone with behavioral therapy reduces illicit opioid use and risk of overdose death. Despite evidence and decades of experience, barriers limit access to treatment and care for individuals with OUD. Barriers include a lack of treatment centers particularly in rural areas, regulations on buprenorphine prescribing, and stigma from the community and health care professionals. While many barriers are longstanding, the coronavirus disease 2019 (COVID\u201019) pandemic\u2010forced isolation and associated stress has exacerbated challenges for individuals with mental health conditions such as OUD. Pharmacists are well\u2010positioned to bridge existing gaps in OUD care, particularly during the COVID\u201019 pandemic. Roles for pharmacists include OUD risk identification and screening, referral of patients to treatment and support programs, ensuring medication access, expanding naloxone access, and advocacy initiatives. This review article identifies barriers to care for patients with OUD during the COVID\u201019 pandemic and explores opportunities and resources for pharmacists to improve OUD care during the pandemic and beyond.<\/jats:p>","DOI":"10.1002\/jac5.1556","type":"journal-article","created":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:22:21Z","timestamp":1635466941000},"page":"203-213","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacists and opioid use disorder care during <scp>COVID<\/scp>\u201019: Call for action"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-9911","authenticated-orcid":false,"given":"Insaf","family":"Mohammad","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"},{"name":"Ambulatory Care Clinical Pharmacy Beaumont Hospital, Dearborn  Dearborn Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Berri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Tutag Lehr","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University  Detroit Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"Substance Abuse and Mental Health Services Administration.Medications for opioid use disorder for healthcare and addiction professionals policymakers patients and families. Treatment Improvement Protocol TIP 63 [Internet]. 2020. [cited 2020 Jul 1]. Available from:https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP20-02-01-006_508.pdf"},{"key":"e_1_2_13_3_1","unstructured":"Substance Abuse and Mental Health Services Administration.Key substance use and mental health indicators in the United States: Results from the 2017 National Survey on Drug Use and Health [Internet]. 2018 [cited 2020 Dec 4]. Available from:https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/cbhsqreports\/NSDUHFFR2017\/NSDUHFFR2017.pdf"},{"key":"e_1_2_13_4_1","unstructured":"Fatal drug overdoses hit a record high last year. Covid\u201019 is making the problem worse. Advisory Board [Internet]. 2020 [cited 2020 Jul 12]. Available from:https:\/\/www.advisory.com\/daily-briefing\/2020\/07\/17\/overdose"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1210"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108210"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2020.1752351"},{"key":"e_1_2_13_8_1","unstructured":"AhmadFB Rossen LMSP.Provisional drug overdose death counts. National Center for Health Statistics [Internet]. 2021 [cited 2021 Jun 4]. Available from:https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"e_1_2_13_9_1","unstructured":"Centers for Disease Control and Prevention. COVID Data Tracker Weekly Review [Internet]. 2021 [cited 2021 Jun 3]. Available from:https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/covid-data\/covidview\/index.html"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000753"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-020-00370-7"},{"key":"e_1_2_13_12_1","unstructured":"U.S. Department of Health and Human Services.HHS Releases New Buprenorphine Practice Guidelines Expanding Access to Treatment for Opioid Use Disorder [Internet]. [cited 2021 Jun 2]. Available from:https:\/\/www.hhs.gov\/about\/news\/2021\/04\/27\/hhs-releases-new-buprenorphine-practice-guidelines-expanding-access-to-treatment-for-opioid-use-disorder.html"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20843"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000678"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1331"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108214"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12307"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/adaw.32657"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000685"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107968"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.07.005"},{"key":"e_1_2_13_22_1","unstructured":"OTP.Guidance for patients quarantined at home with the coronavirus [Internet]. The substance abuse and mental health services administration (SAMHSA). 2020 [cited 2020 Jul 12]. Available from:https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-covid-implementation-guidance.pdf"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.6373"},{"issue":"11","key":"e_1_2_13_24_1","first-page":"117822181769924","article-title":"Access to and payment for office\u2010based buprenorphine treatment in OH","volume":"13","author":"Parran TV","year":"2017","journal-title":"Subst Abuse"},{"key":"e_1_2_13_25_1","unstructured":"Services TUSD of H and H.Practice guidelines for the administration of buprenorphine for treating opioid use disorder. Fed Regist [Internet]. 2021; Available from:https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.3209"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-019-0158-0"},{"key":"e_1_2_13_28_1","unstructured":"Naloxbox.org.Naloxbox [Internet]. 2021 [cited 2021 Feb 15]. Available from:https:\/\/naloxbox.org\/"},{"key":"e_1_2_13_29_1","unstructured":"FDA.FDA requiring labeling changes for opioid pain medicines opioid use disorder medicines regarding naloxone [Internet]. 2020 [cited 2020 Jul 12]. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-requiring-labeling-changes-opioid-pain-medicines-opioid-use-disorder-medicines-regarding"},{"key":"e_1_2_13_30_1","unstructured":"HahnSM.Coronavirus (COVID\u201019) supply chain update [Internet]. FDA Press Announcements. 2020 [cited 2020 Mar 20]. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-supply-chain-update"},{"key":"e_1_2_13_31_1","unstructured":"DuffyJ.India restricts drug exports over Coronavirus fears and international arbitration claims are likely to follow [Internet]. ReedSmith. 2020 [cited 2020 Jul 12]. Available from:https:\/\/communications.reedsmith.com\/40\/3199\/march-2020\/india-restricts-drug-exports-over-coronavirus-fears-and-international-arbitration-claims-are-likely-to-follow(1).asp"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2020.04.153"},{"key":"e_1_2_13_33_1","unstructured":"Docket No. DEA\u2010508A. Adjustments to aggregate production quotas for certain schedule II controlled substances and assessment of annual needs for the list I chemicals ephedrine and pseudoephedrine for 2020 in response to the coronavirus disease 2019 public health emergency. DEA. 2020. Available from:https:\/\/www.dea.gov\/sites\/default\/files\/DEA508A%20-Adjustment2020APQ%20FINAL%20signed%204-6-20.pdf"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102701"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.06.016"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.15353"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-020-00210-w"},{"issue":"3","key":"e_1_2_13_38_1","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.japh.2020.01.001","article-title":"Indiana community pharmacist preceptors' knowledge and perceptions of medication\u2010assisted treatment","volume":"60","author":"Davenport ES","year":"2003","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.05.005"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S282228"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd17.200317"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp150542"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000679"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000525"},{"key":"e_1_2_13_45_1","unstructured":"Centers for Disease Control and Prevetion.Creating community\u2010clinical linkages between community pharmacists and physicians. Atlanta GA: CDC U.S. Department of Health and Human Services; 2017; p. 1\u201323. Available from:https:\/\/www.cdc.gov\/dhdsp\/pubs\/docs\/ccl-pharmacy-guide.pdf"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.9085"},{"issue":"6","key":"e_1_2_13_47_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/cpu.30496","article-title":"Confidentiality of substance use disorder treatment records: Update","volume":"22","author":"Knopf A","year":"2020","journal-title":"Brown University Child and Adolescent Psychopharmacology Update"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.02.006"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7020059"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2002908"},{"key":"e_1_2_13_51_1","unstructured":"American Society of Addiction Medicine.Ensuring access to care in opioid treatment programs [Internet]. 2020 [cited 2021 Jan 29]. Available from:https:\/\/www.asam.org\/Quality-Science\/covid-19-coronavirus\/access-to-care-in-opioid-treatment-program"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1124"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1206"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa503"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/jac5.1171"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/injuryprev-2020-043882"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.04.029"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxab003"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1803982"},{"key":"e_1_2_13_60_1","unstructured":"American Society of Health\u2010System Pharmacists.Expand pharmacists' ability to treat opioid addiction [Internet]. 2021 [cited 2021 Jan 29]. Available from:https:\/\/www.ashp.org\/Advocacy-and-Issues\/Whats-New\/Opioid-Action?loginreturnUrl=SSOCheckOnly"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-019-00728-9"}],"container-title":["JACCP:  JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jac5.1556","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jac5.1556","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jac5.1556","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:57:24Z","timestamp":1760554644000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/jac5.1556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1002\/jac5.1556"],"URL":"https:\/\/doi.org\/10.1002\/jac5.1556","archive":["Portico"],"relation":{},"ISSN":["2574-9870","2574-9870"],"issn-type":[{"value":"2574-9870","type":"print"},{"value":"2574-9870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]},"assertion":[{"value":"2021-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}